MX2022006546A - Reovirus aviar atenuado cepas 94826 c140 y 96139 c140. - Google Patents

Reovirus aviar atenuado cepas 94826 c140 y 96139 c140.

Info

Publication number
MX2022006546A
MX2022006546A MX2022006546A MX2022006546A MX2022006546A MX 2022006546 A MX2022006546 A MX 2022006546A MX 2022006546 A MX2022006546 A MX 2022006546A MX 2022006546 A MX2022006546 A MX 2022006546A MX 2022006546 A MX2022006546 A MX 2022006546A
Authority
MX
Mexico
Prior art keywords
avian reovirus
tenosynovitis
progeny
derivatives
deposited
Prior art date
Application number
MX2022006546A
Other languages
English (en)
Inventor
Holly S Sellers
Original Assignee
Univ Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia filed Critical Univ Georgia
Publication of MX2022006546A publication Critical patent/MX2022006546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12061—Methods of inactivation or attenuation
    • C12N2720/12064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se presentan aislados atenuados de reovirus aviares asociados a la artritis vírica/tenosinovitis en aves de corral, que incluyen la cepa 94826 C140 de reovirus aviar depositada en la ATCC bajo la designación de patente PTA-126077 y la progenie o derivados de la misma y la cepa 96139 C140 de reovirus aviar depositada en la ATCC bajo la designación de patente PTA-126078 y la progenie o derivados de la misma. También se presentan composiciones y métodos para administrar los aislados o las composiciones como vacunas para controlar la artritis vírica/tenosinovitis inducida por reovirus en aves del orden Galliformes.
MX2022006546A 2019-12-02 2020-12-01 Reovirus aviar atenuado cepas 94826 c140 y 96139 c140. MX2022006546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962942426P 2019-12-02 2019-12-02
PCT/US2020/062651 WO2021113206A1 (en) 2019-12-02 2020-12-01 Attenuated avian reovirus strains 94826 c140 and 96139 c140

Publications (1)

Publication Number Publication Date
MX2022006546A true MX2022006546A (es) 2022-07-01

Family

ID=76221714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006546A MX2022006546A (es) 2019-12-02 2020-12-01 Reovirus aviar atenuado cepas 94826 c140 y 96139 c140.

Country Status (7)

Country Link
US (1) US20230000972A1 (es)
EP (1) EP4069289A4 (es)
JP (1) JP2023504225A (es)
CN (1) CN114828883A (es)
BR (1) BR112022010687A2 (es)
MX (1) MX2022006546A (es)
WO (1) WO2021113206A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116478937B (zh) * 2023-06-12 2023-08-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 基因iii型禽呼肠孤病毒变异株及其在制备疫苗中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2708316C2 (ru) * 2014-01-29 2019-12-05 Дзе Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк. Вакцины на основе реовирусов птиц
WO2017210262A1 (en) * 2016-06-02 2017-12-07 Steven Baranowitz Prevention and treatment of viral infections

Also Published As

Publication number Publication date
CN114828883A (zh) 2022-07-29
WO2021113206A1 (en) 2021-06-10
JP2023504225A (ja) 2023-02-01
EP4069289A1 (en) 2022-10-12
US20230000972A1 (en) 2023-01-05
BR112022010687A2 (pt) 2022-08-23
EP4069289A4 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
WO2017176620A3 (en) SOLUBLE C5aR ANTAGONISTS
NZ597182A (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AR084441A1 (es) Mutantes tipo “papel de lija” (sand paper) de bacillus y metodos de uso de los mismos para mejorar el crecimiento vegetal, promover la salud de plantas y controlar enfermedades y plagas
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
MX2022003435A (es) Desarrollo de una vacuna novedosa atenuada viva contra la peste porcina africana basada en la eliminacion del gen i177l.
BRPI0518568A2 (pt) mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
Xiao et al. The newly emerging duck-origin goose parvovirus in China exhibits a wide range of pathogenicity to main domesticated waterfowl
CO2019010062A2 (es) Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens
MX2021014525A (es) Adenovirus modificados.
MX2014005754A (es) Bacterias de ácido láctico y su uso como suplementos dietéticos para aves de corral.
CR20220205A (es) INHIBICIÓN DE INTEGRINA a4ß7 HUMANA
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
MX2019006992A (es) Vacunacion eficaz contra cepas europeas del virus del sindrome reproductivo y respiratorio porcino (prrs) previo al destete.
MX2022006546A (es) Reovirus aviar atenuado cepas 94826 c140 y 96139 c140.
MX2021008017A (es) Formulaciones de colagenasa y metodos de produccion de las mismas.
WO2021050927A3 (en) Yeast-hydrolysate compositions and methods of their use
MX2015016765A (es) Celulas aviares para la produccion mejorada de virus.
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
CN103272230B (zh) 番鸭专用的三联活疫苗
MX2011009579A (es) Cepas novedosas de hongos coprinus comatus y tremella mesenterica novedosas, productos y extractos de las mismas y composiciones que las comprenden.
CO2020010533A2 (es) Novedoso bacteriófago de salmonella heidelberg sal-hep-1 y su uso para inhibir el crecimiento de las bacterias de salmonella heidelberg
MX2021000949A (es) Nueva cepa de virus atenuada y su uso como una vacuna.
MX2017006638A (es) Metodos y composiciones para el incremento de la masa corporal magra y minimizar la ganancia de grasa corporal y el control del peso.
TW200710224A (en) Attenuated avian infectious bronchitis virus vaccines